CL2023001392A1 - Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8 - Google Patents
Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8Info
- Publication number
- CL2023001392A1 CL2023001392A1 CL2023001392A CL2023001392A CL2023001392A1 CL 2023001392 A1 CL2023001392 A1 CL 2023001392A1 CL 2023001392 A CL2023001392 A CL 2023001392A CL 2023001392 A CL2023001392 A CL 2023001392A CL 2023001392 A1 CL2023001392 A1 CL 2023001392A1
- Authority
- CL
- Chile
- Prior art keywords
- tspan8
- antibody
- cancer cell
- peritoneal
- antibodies
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 abstract 3
- 102100032802 Tetraspanin-8 Human genes 0.000 abstract 3
- 101000794187 Homo sapiens Tetraspanin-18 Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 102100030175 Tetraspanin-18 Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un objetivo de la presente invención es proporcionar un anticuerpo anti-TSPAN8/antiCD3 específico y un anticuerpo anti-TSPAN8 utilizable en el tratamiento o prevención en un ser humano. Se inmunizó un ratón productor de anticuerpos monoclonales humanos con una célula cancerosa diseminada peritoneal aislada de un paciente, para obtener un anticuerpo 16B11 y un anticuerpo 16B12 que se unen selectivamente a una célula cancerosa diseminada peritoneal. Estos anticuerpos eran anticuerpos anti-TSPAN8 que se unen a la región de las posiciones de aminoácidos 126 a 155 de TSPAN8 y mostraron una fuerte actividad de unión a TSPAN8 expresada en la célula cancerosa diseminada peritoneal. Además, un anticuerpo biespecífico anti-TSPAN8 (16B11) -anti-CD3 producido sobre la base de la secuencia de 16B11 exhibió una actividad citotóxica contra la célula cancerosa que expresa TSPAN8 in vitro, ejerció una acción antitumoral en ratones portadores de células cancerosas que expresan TSPAN in vivo, y prolongaron la vida útil de los ratones modelo de diseminación peritoneal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020189988 | 2020-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001392A1 true CL2023001392A1 (es) | 2023-10-13 |
Family
ID=81601338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001392A CL2023001392A1 (es) | 2020-11-16 | 2023-05-15 | Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8 |
Country Status (18)
Country | Link |
---|---|
US (2) | US11897954B2 (es) |
EP (1) | EP4245855A1 (es) |
JP (2) | JP7078237B1 (es) |
KR (1) | KR20230108288A (es) |
CN (1) | CN116635071A (es) |
AR (1) | AR124063A1 (es) |
AU (1) | AU2021378575A1 (es) |
CA (1) | CA3200860A1 (es) |
CL (1) | CL2023001392A1 (es) |
CO (1) | CO2023007734A2 (es) |
CR (1) | CR20230244A (es) |
DO (1) | DOP2023000096A (es) |
EC (1) | ECSP23034684A (es) |
IL (1) | IL302544A (es) |
MX (1) | MX2023005346A (es) |
PE (1) | PE20240224A1 (es) |
TW (1) | TW202229353A (es) |
WO (1) | WO2022102768A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202404638A (zh) * | 2022-04-13 | 2024-02-01 | 日商安斯泰來製藥股份有限公司 | 抗tspan8-抗cd3雙特異性抗體之與pd-1訊息抑制劑之組合在癌治療的用途 |
WO2023219121A1 (ja) * | 2022-05-12 | 2023-11-16 | アステラス製薬株式会社 | 抗taa-抗cd3多重特異性抗体 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
US9040671B2 (en) | 2010-07-23 | 2015-05-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for cancer management targeting Co-029 |
KR101238594B1 (ko) | 2010-07-27 | 2013-02-28 | 엘지이노텍 주식회사 | 스티어링 시스템의 토크 센서 |
JP6159010B2 (ja) | 2013-03-15 | 2017-07-05 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | テトラスパニン8に対するハイブリドーマクローンおよびモノクローナル抗体 |
KR101906558B1 (ko) | 2014-02-28 | 2018-10-11 | (재) 스크립스코리아항체연구원 | Tspan8에 특이적인 신규 항체 및 이의 용도 |
KR20150130115A (ko) | 2014-05-13 | 2015-11-23 | 연세대학교 산학협력단 | 상온 대기압 플라즈마를 이용한 치은 섬유아세포의 세포활성도 촉진 방법 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
JP7072792B2 (ja) | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
-
2021
- 2021-11-15 CR CR20230244A patent/CR20230244A/es unknown
- 2021-11-15 MX MX2023005346A patent/MX2023005346A/es unknown
- 2021-11-15 CA CA3200860A patent/CA3200860A1/en active Pending
- 2021-11-15 JP JP2022502914A patent/JP7078237B1/ja active Active
- 2021-11-15 TW TW110142388A patent/TW202229353A/zh unknown
- 2021-11-15 KR KR1020237019446A patent/KR20230108288A/ko unknown
- 2021-11-15 WO PCT/JP2021/041839 patent/WO2022102768A1/ja active Application Filing
- 2021-11-15 PE PE2023001609A patent/PE20240224A1/es unknown
- 2021-11-15 AU AU2021378575A patent/AU2021378575A1/en active Pending
- 2021-11-15 US US17/639,783 patent/US11897954B2/en active Active
- 2021-11-15 EP EP21892013.0A patent/EP4245855A1/en active Pending
- 2021-11-15 CN CN202180076884.7A patent/CN116635071A/zh active Pending
- 2021-11-15 AR ARP210103152A patent/AR124063A1/es unknown
- 2021-11-15 IL IL302544A patent/IL302544A/en unknown
-
2022
- 2022-03-09 JP JP2022036009A patent/JP2022079486A/ja active Pending
-
2023
- 2023-05-11 EC ECSENADI202334684A patent/ECSP23034684A/es unknown
- 2023-05-15 CL CL2023001392A patent/CL2023001392A1/es unknown
- 2023-05-15 DO DO2023000096A patent/DOP2023000096A/es unknown
- 2023-06-14 CO CONC2023/0007734A patent/CO2023007734A2/es unknown
- 2023-12-26 US US18/396,461 patent/US20240166736A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230108288A (ko) | 2023-07-18 |
US11897954B2 (en) | 2024-02-13 |
JPWO2022102768A1 (es) | 2022-05-19 |
JP7078237B1 (ja) | 2022-05-31 |
US20230348587A1 (en) | 2023-11-02 |
JP2022079486A (ja) | 2022-05-26 |
AU2021378575A1 (en) | 2023-06-22 |
CN116635071A (zh) | 2023-08-22 |
MX2023005346A (es) | 2023-05-22 |
CO2023007734A2 (es) | 2023-06-30 |
ECSP23034684A (es) | 2023-06-30 |
IL302544A (en) | 2023-07-01 |
DOP2023000096A (es) | 2023-06-15 |
PE20240224A1 (es) | 2024-02-16 |
CR20230244A (es) | 2023-07-12 |
US20240166736A1 (en) | 2024-05-23 |
CA3200860A1 (en) | 2022-05-19 |
AR124063A1 (es) | 2023-02-08 |
TW202229353A (zh) | 2022-08-01 |
EP4245855A1 (en) | 2023-09-20 |
WO2022102768A1 (ja) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023001392A1 (es) | Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8 | |
CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
CR20190497A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20210287A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
AU2019250206A1 (en) | Novel immunogenic peptides | |
CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
EA201691836A1 (ru) | Антитела к mcam и соответствующие способы их применения | |
ECSP18009949A (es) | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana | |
EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
EA202090922A1 (ru) | Композиции и способы истощения cd2+ клеток | |
AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
CO2020007275A2 (es) | Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas | |
BR112023021950A2 (pt) | Anticorpo bispecífico anti-cldn4/anti-cd137 | |
PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
CO2019002477A2 (es) | Anticuerpo para tratar enfermedades autoinmunes | |
MX2022003243A (es) | Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos. | |
CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
MX2022014231A (es) | Conjugados de anticuerpo-farmaco que se enfocan a la uparap. | |
MX2022008050A (es) | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. | |
PL425133A1 (pl) | Mutanty punktowe czynnika B oraz białka C2, sposób wzmacniania aktywności przeciwciał antynowotworowych, kompozycja farmaceutyczna oraz zastosowanie mutantów | |
AR082221A1 (es) | Anticuerpos monoclonales anti-rhd (rhesus d) |